Deutsch
English
Español
Français
Nederlands
Português
Ebola Outbreak in DR Congo and Uganda Claims Nearly 1,000 Lives
The ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda has killed at least 999 people, according to the latest update from the Congolese Ministry of Health. Caused by the rare Bundibugyo virus (BDBV), this is now the third-largest Ebola outbreak on record and is spreading faster than any previous outbreak. As of July 2026, over 2,473 confirmed cases have been reported in the DRC, with 737 patients currently in isolation or hospital care. The virus has also spread to neighboring Uganda, where two deaths have been confirmed, and one case was reported in France linked to travel from the DRC.
The 2026 Ebola outbreak in Africa has prompted the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC) on May 17, 2026. The Bundibugyo species has no approved vaccine or specific treatment, though clinical trials for therapies and diagnostics are underway.
What Is the Bundibugyo Virus?
Bundibugyo virus (BDBV) is a species of ebolavirus first discovered in 2007 in Bundibugyo District, western Uganda. It is one of four ebolaviruses that cause Ebola virus disease (EVD) in humans. Unlike the more well-known Zaire ebolavirus (which caused the 2014-2016 West Africa epidemic), BDBV has no licensed vaccine or targeted antiviral therapy. The virus is classified as a WHO Risk Group 4 Pathogen and a CDC Category A Bioterrorism Agent, requiring Biosafety Level 4 containment.
Symptoms of BDBV infection include fever, severe headache, muscle pain, vomiting, diarrhea, and in severe cases, unexplained hemorrhage. The case fatality rate for Bundibugyo virus outbreaks has historically ranged from 25% to 40%, but the current outbreak's rapid spread has overwhelmed health systems.
Why Is This Outbreak Spreading So Fast?
Several factors are driving the unprecedented speed of this outbreak. According to the WHO and Africa CDC, the outbreak is occurring in a region already facing a humanitarian crisis, with remote, densely populated areas, ongoing armed conflict, and high population movement across borders. The CDC reports that the outbreak surpassed 1,000 confirmed cases within 40 days—compared to 235 days for the 2018 outbreak in DRC. Authorities warn that for 80% of new cases, the source of infection is unknown, meaning community transmission is outpacing contact tracing efforts.
"If we do not stop this outbreak today, it could become one of the worst Ebola outbreaks the world has ever seen," said Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention. He has called for intensified international response efforts.
In some affected areas, villages are so remote they can only be reached by helicopter. "Speed is our only defense against the spread of Ebola," said Headly Tah of the UN Humanitarian Air Service. The humanitarian response in conflict zones faces additional challenges from attacks on healthcare workers and misinformation campaigns.
International Response and Funding
The global community has mobilized significant resources. The Netherlands announced an additional €4 million in emergency funding. The Global Fund approved US$4.6 million for malaria prevention in DRC to help distinguish Ebola cases from malaria, as symptoms overlap. The European & Developing Countries Clinical Trials Partnership (EDCTP) activated €4 million for research on surveillance, diagnostics, and broad-spectrum therapeutics, building on €124.9 million in prior Ebola investments.
The WHO added the first diagnostic test for Bundibugyo virus to its Emergency Use Listing in July 2026, enabling faster case detection. Patient enrolment has begun in clinical trials for experimental treatments, though no licensed therapy exists yet. The WHO's response to health emergencies includes deploying over 400 CDC personnel, with more than 120 deployed to affected countries.
Regional and Global Risk
While the WHO assesses the global risk as low, the regional risk remains high. Cases have been confirmed in five DRC provinces (Haut-Uele, Ituri, Nord-Kivu, Sud-Kivu, and Tshopo) and in Kampala, Uganda. The CDC has implemented public health entry screening for travelers from affected regions and recommends avoiding non-essential travel to affected DRC provinces. No cases have been reported in the United States.
The outbreak has also disrupted routine health services. In June 2026, healthcare workers in eastern DRC went on strike due to safety concerns after attacks on treatment centers. A fire at an Ebola treatment center in July 2026 caused one death and led to patients fleeing, further complicating containment efforts.
Frequently Asked Questions
What is the Bundibugyo virus?
Bundibugyo virus (BDBV) is a species of ebolavirus that causes Ebola virus disease. It was first identified in Uganda in 2007. Unlike Zaire ebolavirus, there is no licensed vaccine or specific treatment for BDBV.
How does Ebola spread?
Ebola spreads through direct contact with bodily fluids (blood, vomit, feces, semen) of an infected person or contaminated materials. It is not airborne.
What are the symptoms of Ebola?
Symptoms include fever, fatigue, muscle pain, headache, vomiting, diarrhea, and in severe cases, internal and external bleeding. Symptoms appear 2 to 21 days after exposure.
Is there a vaccine for this outbreak?
No approved vaccine exists for the Bundibugyo virus. Vaccines for Zaire ebolavirus (like Ervebo) are not effective against BDBV. Clinical trials for new vaccines and treatments are ongoing.
What is being done to stop the outbreak?
WHO, CDC, Africa CDC, and national authorities are conducting surveillance, contact tracing, community engagement, and clinical trials. Emergency funding has been allocated, and travel restrictions are in place for affected regions.
Follow Discussion